ArticleScientific reports2026
Ginsenoside Rh4-regulated macrophage polarization and oxidative stress in septic myocardial injury.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Septic cardiomyopathy (SCM) is a severe complication of sepsis. The therapeutic potential of Ginsenoside Rh4 (Rh4) in SCM remains unclear. This study aimed to investigate the effects and mechanisms of Rh4 on SCM using both in vivo and in vitro approaches. In the in vivo experiments, Rh4 significantly reduced the mortality rate in SCM mice, improved ejection fraction and diastolic function, and protected myocardial cell mitochondria, thereby alleviating myocardial cell injury. Transcriptomic sequencing, ELISA, and PCR results suggested that Rh4 reduced inflammatory cytokines in myocardial tissues, likely through the inhibition of the NF-κB signaling pathway. This effect was associated with a reduction in pro-inflammatory M1 macrophages and an increase in the proportion of reparative M2 macrophages. Additionally, Rh4 alleviated myocardial cell apoptosis and attenuated myocardial fibrosis at later stages. In vitro, we found that Rh4 reduced LPS-induced macrophage polarization and promoted the polarization of macrophages into anti-inflammatory M2 macrophages. Moreover, flow cytometry analysis revealed that Rh4 decreased reactive oxygen species (ROS) production in HL-1 cardiomyocytes, with the mechanism linked to the activation of the Keap1/Nrf2/HO-1 signaling pathway. Finally, Rh4 treatment significantly inhibited the pro-apoptotic effects of LPS on HL-1 cells. In conclusion, Rh4 improves heart function by reducing macrophage polarization and ROS generation, protecting myocardial cell mitochondria, and reducing myocardial cell apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.